Egyszerű nézet

dc.contributor.author Mészáros T
dc.contributor.author Szénási, Gábor
dc.contributor.author Rosivall, László
dc.contributor.author Szebeni, János
dc.contributor.author Dézsi, László
dc.date.accessioned 2017-06-12T12:45:21Z
dc.date.available 2017-06-12T12:45:21Z
dc.date.issued 2015
dc.identifier 84931090679
dc.identifier.citation pagination=257-262; journalVolume=7; journalIssueNumber=3; journalTitle=EUROPEAN JOURNAL OF NANOMEDICINE;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/2549
dc.identifier.uri doi:10.1515/ejnm-2015-0022
dc.description.abstract The complement (C) activating effect of zymosan and liposomal drugs (AmBisome, Caelyx) leads to significant C consumption in rats, dogs, pigs and other species in vivo, as reflected by a fall in hemolytic complement activity (HCA) of their plasma. However, the acute C activating effect of zymosan and liposomal drugs is unclear in the mouse. Therefore, using sheep red blood cells, we assayed the HCA of plasma obtained from apolipoprotein E-deficient (ApoE) as well as from background C57BL/6 (BL6) mice. Intravenous (i.v.) administration of C activators led to a significant rise (up to 40%) in HCA of the plasma. The HCA steadily rose up to 30 min in ApoE mice, while it peaked at 3 min in BL6 mice, returning to baseline thereafter. The elevated HCA after IV injection of C activators is "paradoxical" in mice, since it implies an increase rather than a decrease in C levels in the blood. One possible explanation of the phenomenon is hemoconcentration due to anaphylatoxin-induced capillary leakage, resulting in an apparent rise of HCA. In conclusion, these preliminary observations highlight, for the first time, a species-dependent opposing impact of C activation and the resulting anaphylatoxin actions on hemolytic complement activity. © 2015 by De Gruyter 2015.
dc.relation.ispartof urn:issn:1662-5986
dc.title Paradoxical rise of hemolytic complement in the blood of mice during zymosan- and liposome-induced CARPA: A pilot study
dc.type Journal Article
dc.date.updated 2015-11-23T13:24:33Z
dc.language.rfc3066 en
dc.identifier.mtmt 2919063
dc.contributor.department SE/AOK/I/Kórélettani Intézet
dc.contributor.department SE/KSZE/Nanomedicina Kutatási és Oktatási Központ [2016.07.31]
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet